The National Immunobiological Company (part of Rostec State Corporation), Pharmstandard and Kedrion Biopharma (Italy) signed an agreement to establish Kirov Plasma, a joint-stock company. The company will develop and implement a program for manufacturing, in the Russian Federation, the medicinal products derived from human blood plasma based on facilities of Kirov plant. The share of Kedrion Biopharma in the authorized capital is 25%, while Nacimbio and Pharmstandard will each hold a stake of 37.5%.
Kirov Plasma will provide complete technical equipment for the enterprise and validate the manufacturing of medicines derived from human blood plasma. It is expected that the base project will be ready in Q3 2017.
“We have the task of eliminating Russia’s dependence on imports of biological and medicinal products. Today, 100% of coagulation factors VIII and IX, that are vital for patients with hemophilia, are purchased abroad. Overall, up to 90% of medicines in the blood product segment are imported. After the plant reaches its production capacity, the need for albumin, immunoglobulin and coagulation factors VIII and IX of the Russian healthcare system will be completely satisfied,” said Maryam Khubieva, CEO of Nacimbio.